Cold thinking on ten hot issues in the treatment of early breast cancer / 中华外科杂志
Chinese Journal of Surgery
;
(12): 213-218, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-935602
ABSTRACT
With the development of new strategies like target therapy and immunotherapy, early breast cancer treatment has become more standardized, and the interval of disease free survival has been extended. Although guidelines and expert consensus have provided supports for clinical decision making, there are still some controversial issues in clinical practice, attributing to different treatment concepts, product indications and accessibility. These controversial issues would eventually affect the treatment of early breast cancer. This year in 2021, the approval of new indications of drugs like abemaciclib and the popularity of dual anti-human epidermal growth factor receptor 2 targeted drugs have promoted the change of treatment modalities for different types of early breast cancer. To this end, ten hot topics of early breast cancer are summarized according to their different molecular typing and treatment stages for discussion.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias de la Mama
/
Receptor ErbB-2
/
Supervivencia sin Enfermedad
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio pronóstico
/
Investigación cualitativa
Límite:
Femenino
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Surgery
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS